Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

NCT06063213 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-03-04

No results posted yet for this study

Summary

To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.

Conditions

  • Transplant Complication

Sponsors & Collaborators

  • Transplant Genomics, Inc.

    collaborator INDUSTRY
  • University of Florida

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2026-10-15
Completion
2026-10-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06063213 on ClinicalTrials.gov